AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

673.808

-2.556-0.38%

Number of Gainers:10

Number of Losers:14

Number of Flat:19

PE:- -

High:685.239

Open:680.163

Low:669.907

Close:676.364

Volume:63.38M

Turnover:92.19M

Market Cap:96.84B

Float Cap:93.72B

Loading ...

CSL and Alentis Announce Global Partnership to Develop and Commercialise Lixudebart for Rare Kidney and Liver Diseases

THOMSON REUTERS

Australia's CSL Strikes Kidney, Liver Disease Drug Deal Worth up to $1.6 Billion

To Pay Alentis $355 Mln Upfront and up to $1.2 Bln in Milestones

THOMSON REUTERS

To Fully Fund Phase 2 and Phase 3 Trials for Lixudebart

THOMSON REUTERS

CSL Limited-CSL Enters Exclusive Agreement with Alentis Therapeutics

THOMSON REUTERS

Enters Agreement with Alentis to Co-Develop and Co-Promote Lixudebart

THOMSON REUTERS

How Honeycomb Qualification At Hexcel (HXL) Has Changed Its Investment Story

Simply Wall St.

What Has Actually Changed At PolyNovo (PNV)?

Simply Wall St.

Orthocell Ltd-Change of Auditor

THOMSON REUTERS

US FDA Advisers Recommend Flu Vaccine Strains for 2027 Southern Hemisphere Season

Starpharma Holdings Appoints Russell Basser as Chair

Starpharma - Rob Thomas Ao to Retire as Chair at Conclusion of 2026 AGM

THOMSON REUTERS

Starpharma Holdings Ltd-Chair and Deputy Chair Appointments

THOMSON REUTERS

Imricor's Stock Weakness Creates 'Great Buying Opportunity'

ASX Growth Companies With High Insider Ownership September 2026

Simply Wall St.

3 Australian Biotech Stocks With Up To 77% Fair Value Upside

Simply Wall St.

Thailand Posts $2.4 Billion Current Account Surplus in August

MT Newswires Live

CSL Still Generates Caution Despite Rerate

Immutep Receives A$ 856,669 Australian R&D Tax Incentive Cash Rebate

Cann Group Files 2026 Corporate Governance Statement With ASX

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":673.8078,"timestamp":1791435599598,"preClose":676.3637,"halted":0,"volume":63375929,"delay":0,"changeRate":-0.003779,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-2.555908,"latestTime":"10-08 16:00:00 AEDT","open":680.1626,"high":685.2389,"low":669.9068,"amount":92191055,"amplitude":0.022668,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791500400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1791414000000,1791435600000]],"turnoverRate":0.00252,"increases":9,"decrements":13,"flats":20,"marketCap":96835706888,"floatMarketCap":93723403428.875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":685.2389,"amplitude":0.022668,"preClose":676.3637,"low":669.9068,"latestPrice":673.8078,"volume":63375929,"delay":0,"open":680.1626,"prevYearClose":644.3692,"prevWeekClose":654.21,"prevMonthClose":689.549,"prevQuarterClose":689.549,"fiveDayClose":666.631,"twentyDayClose":646.103,"sixtyDayClose":495.646,"secType":"PLATE","market":"AU","turnoverRate":0.00252,"marketCap":96835706888,"floatMarketCap":93723403428.875,"timestamp":1791435599598,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":10,"down":14,"flat":19},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673776854","title":"CSL and Alentis Announce Global Partnership to Develop and Commercialise Lixudebart for Rare Kidney and Liver Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776854","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776854?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:42","pubTimestamp":1791150151,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUABRZMKD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673750477","title":"Australia's CSL Strikes Kidney, Liver Disease Drug Deal Worth up to $1.6 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2673750477","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673750477?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:37","pubTimestamp":1791149849,"startTime":"0","endTime":"0","summary":"Australia's CSL strikes kidney, liver disease drug deal worth up to $1.6 billionOct 5 -Australia's CSLCSL.AXsaid on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion before development funding.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nL1N45Q05Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","CSL.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775745","title":"To Pay Alentis $355 Mln Upfront and up to $1.2 Bln in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775745?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775723","title":"To Fully Fund Phase 2 and Phase 3 Trials for Lixudebart","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775723","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775723?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775717","title":"CSL Limited-CSL Enters Exclusive Agreement with Alentis Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775717?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775710","title":"Enters Agreement with Alentis to Co-Develop and Co-Promote Lixudebart","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775710?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7067","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672174636","title":"How Honeycomb Qualification At Hexcel (HXL) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2672174636","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672174636?lang=en_us&edition=fundamental","pubTime":"2026-10-03 01:28","pubTimestamp":1790962113,"startTime":"0","endTime":"0","summary":"Hexcel showcased new composite materials at CAMX 2026, including NCAMP-qualified HexWeb HRH-10 honeycomb, expanded U.S. production of fast-curing HexPly M901, and an upgraded Vented Flex-Core aluminum honeycomb for complex aerospace structures.\nThe NCAMP qualification of HRH-10 creates the first public aerospace honeycomb database, which can cut customer design and certification costs and potentially increase Hexcel’s role in future composite programs.\nWe will now assess how Hexcel’s...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3021000-choice1-card/1788942963390","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3021000-choice1-card/1788942963390"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/how-honeycomb-qualification-at-hexcel-hxl-has-changed-its-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/how-honeycomb-qualification-at-hexcel-hxl-has-changed-its-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","LU0053671581.USD","HXL.AU","HXL","LU0240878834.USD","BK7067","ROKT","BK4187","BZZ","LU0205193047.USD","LU0205194284.USD","LU0240877869.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672199877","title":"What Has Actually Changed At PolyNovo (PNV)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672199877","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672199877?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:29","pubTimestamp":1790933377,"startTime":"0","endTime":"0","summary":"If you had paused on PolyNovo in late 2025 because the bullish and bearish analyst targets seemed too far apart to trust, the past year probably feels like a narrow escape. Investors who held PolyNovo over the past year are down 39.5%, including dividends. Recent results show higher revenue with a thinner net margin. The key question is simple: Which early clues about pricing power, product concentration, or regulation would you have wanted to stress test before committing?\nIf the move has...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6022000-choice1-card/1788992506868","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6022000-choice1-card/1788992506868"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/what-has-actually-changed-at-polynovo-pnv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/what-has-actually-changed-at-polynovo-pnv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7126","PNV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672793108","title":"Orthocell Ltd-Change of Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2672793108","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672793108?lang=en_us&edition=fundamental","pubTime":"2026-10-02 09:04","pubTimestamp":1790903059,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nTUECB442V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672766765","title":"US FDA Advisers Recommend Flu Vaccine Strains for 2027 Southern Hemisphere Season","url":"https://stock-news.laohu8.com/highlight/detail?id=2672766765","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672766765?lang=en_us&edition=fundamental","pubTime":"2026-10-02 01:01","pubTimestamp":1790874064,"startTime":"0","endTime":"0","summary":"US FDA advisers recommend flu vaccine strains for 2027 Southern Hemisphere seasonOct 1 (Reuters)-A panel of advisers to the US FDA on Thursday recommended the virus strains vaccine manufacturers shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nL4N45M0VF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7067","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672073681","title":"Starpharma Holdings Appoints Russell Basser as Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2672073681","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672073681?lang=en_us&edition=fundamental","pubTime":"2026-10-01 09:51","pubTimestamp":1790819484,"startTime":"0","endTime":"0","summary":"BRIEF-Starpharma Holdings Appoints Russell Basser As ChairOct 1 (Reuters)-Starpharma Holdings LtdSPL.AX:CHAIR AND DEPUTY CHAIR APPOINTMENTSAPPOINTS RUSSELL BASSER AS CHAIR AND DAVID MCINTYRE AS DEPUTY","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUE5DHXTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","SPL.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672832735","title":"Starpharma - Rob Thomas Ao to Retire as Chair at Conclusion of 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2672832735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672832735?lang=en_us&edition=fundamental","pubTime":"2026-10-01 08:44","pubTimestamp":1790815481,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUE5DHXTY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","SPL.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672673588","title":"Starpharma Holdings Ltd-Chair and Deputy Chair Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2672673588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672673588?lang=en_us&edition=fundamental","pubTime":"2026-10-01 08:44","pubTimestamp":1790815481,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUE5DHXTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPL.AU","BK7096","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672710738","title":"Imricor's Stock Weakness Creates 'Great Buying Opportunity'","url":"https://stock-news.laohu8.com/highlight/detail?id=2672710738","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672710738?lang=en_us&edition=fundamental","pubTime":"2026-10-01 07:18","pubTimestamp":1790810280,"startTime":"0","endTime":"0","summary":"2318 GMT - A more than 20% fall in the share price of Imricor Medical Systems since it entered the ASX 300 index in early September creates a great buying opportunity for investors, according to its bull at Morgans. Imricor ended Wednesday at A$1.585, having traded as high as A$2.07 in August. Morgans suggests seasonal weakness and rising interest rates may have contributed to the share-price fall. Recent news flow has been positive. \"As we move into a seasonally stronger part of the year, together with our view that material news flow  is expected, we believe the share price should move back over A$2.00,\" Morgans' analyst Scott Power says. Morgans has a speculative buy call on Imricor.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7503","BK7007","IMR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672411738","title":"ASX Growth Companies With High Insider Ownership September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672411738","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672411738?lang=en_us&edition=fundamental","pubTime":"2026-10-01 03:08","pubTimestamp":1790795293,"startTime":"0","endTime":"0","summary":"In the wake of the recent RBA rate increase, the Australian market is experiencing a period of volatility, with mixed signals from global markets and fluctuating commodity prices adding to investor uncertainty. Amidst these conditions, growth companies with high insider ownership can offer unique insights into potential resilience and alignment between management and shareholder interests, making them noteworthy in today's economic climate.","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/asx-growth-companies-with-high-insider-ownership-september-2-5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/asx-growth-companies-with-high-insider-ownership-september-2-5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4108","OZR.AU","OZF.AU","IOZ.AU","BBOZ.AU","E200.AU","AV1.AU","AEM.AU","BK7095","BK7023","GIVE.AU","SKS.AU","ZYAU.AU","STW.AU","AR1.AU","PDI.AU","IISV.AU","SLF.AU","IQ","QFN.AU","SPL.AU","BK7093","MSB.AU","BK7137","BK7017","BK7084","VAP.AU","BK4531","IMLC.AU","BK7501","BK4526","EIGA.AU","BK7508","XJO.AU","DACE.AU","GEAR.AU","FRS.AU","BK4552","IIGF.AU","QRE.AU","WZR.AU","EMR.AU","XAO.AU","VAS.AU","EIQ.AU","BK7104","BEAR.AU","GYG.AU","ELS.AU","XKO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672738443","title":"3 Australian Biotech Stocks With Up To 77% Fair Value Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2672738443","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672738443?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:20","pubTimestamp":1790763656,"startTime":"0","endTime":"0","summary":"Australia’s inflation rate sitting at 4% and interest rates at a 15 year high of 4.6% are squeezing many growth stories. Yet that pressure also pushes investors toward companies with solid balance sheets and clear funding runways. That matters for Australian biotechnology stocks, where capital access can make or break a breakthrough. This article highlights three listed biotech opportunities screened for financial resilience and reasonable value.\nThe three biotech stocks covered below are a...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLF.AU","BEAR.AU","OZR.AU","STW.AU","ZYAU.AU","XAO.AU","OZF.AU","GIVE.AU","IIGF.AU","NVIB","BK7508","VAS.AU","IOZ.AU","XBI","XKO.AU","VLS.AU","BK4581","GEAR.AU","IMLC.AU","VAP.AU","E200.AU","BBOZ.AU","QRE.AU","MYX.AU","BK4585","BK7096","XBIX","EIGA.AU","CUV.AU","BK4588","DACE.AU","BK7067","IISV.AU","XJO.AU","QFN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671827184","title":"Thailand Posts $2.4 Billion Current Account Surplus in August","url":"https://stock-news.laohu8.com/highlight/detail?id=2671827184","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671827184?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:55","pubTimestamp":1790754907,"startTime":"0","endTime":"0","summary":"Thailand's current account position recorded a surplus of $2.4 billion in August, according to data from the Bank of Thailand (BOT) released on Wednesday.The reading compared with a $1.6 billion deficit recorded in the previous month.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BOT","BK7508","BK7502","BOT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671227775","title":"CSL Still Generates Caution Despite Rerate","url":"https://stock-news.laohu8.com/highlight/detail?id=2671227775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671227775?lang=en_us&edition=fundamental","pubTime":"2026-09-30 12:52","pubTimestamp":1790743920,"startTime":"0","endTime":"0","summary":"0452 GMT - CSL still generates caution at Macquarie despite the stock's recent rerate. Analysts at the investment bank keep a neutral rating on the Australia-based pharmaceutical company, observing that a 58% share-price rise over three months came despite earnings downgrades. They think that near-term catalysts will probably support the current rerating, but tell clients in a note that they are cautious on the medium-term outlook due to uncertainty over the impact on demand of complement-inhibitor therapies, albumin collections, and the process to appoint a new permanent CEO. Macquarie raises its target price on the stock 31% to 174.00 Australian dollars. Shares are up 1.4% at A$184.25.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7511","CSL.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671226246","title":"Immutep Receives A$ 856,669 Australian R&D Tax Incentive Cash Rebate","url":"https://stock-news.laohu8.com/highlight/detail?id=2671226246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671226246?lang=en_us&edition=fundamental","pubTime":"2026-09-30 09:15","pubTimestamp":1790730903,"startTime":"0","endTime":"0","summary":"Immutep receives A$ 856,669 Australian R&D tax incentive cash rebateImmutep received an A$ 856,669 cash rebate under Australia’s R&D tax incentive program for eligible 2025 fiscal-year spending.AusInd","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL3wCmPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671299242","title":"Cann Group Files 2026 Corporate Governance Statement With ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2671299242","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671299242?lang=en_us&edition=fundamental","pubTime":"2026-09-30 09:07","pubTimestamp":1790730434,"startTime":"0","endTime":"0","summary":"Cann Group ( ($AU:CAN) ) has provided an update. Cann Group Limited has lodged its corporate governance statement for the year ended 30 June 2026, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cann-group-files-2026-corporate-governance-statement-with-asx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cann-group-files-2026-corporate-governance-statement-with-asx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK7502","CAN.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":92,"code":"91000000","status":"200"}]}}